Charles Schwab Investment Management Inc Trevi Therapeutics, Inc. Transaction History
Charles Schwab Investment Management Inc
- $515 Billion
- Q3 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Trevi Therapeutics, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 150,918 shares of TRVI stock, worth $415,024. This represents 0.0% of its overall portfolio holdings.
Number of Shares
150,918
Previous 150,918
-0.0%
Holding current value
$415,024
Previous $449,000
12.25%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding TRVI
# of Institutions
94Shares Held
57.1MCall Options Held
136KPut Options Held
5.4K-
Nea Management Company, LLC Timonium, MD11.4MShares$31.3 Million2.9% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA7.38MShares$20.3 Million1.33% of portfolio
-
Rubric Capital Management LP New York, NY5.03MShares$13.8 Million0.47% of portfolio
-
Viking Global Investors LP4.4MShares$12.1 Million0.06% of portfolio
-
Vr Adviser, LLC New York, NY3.42MShares$9.41 Million1.18% of portfolio
About Trevi Therapeutics, Inc.
- Ticker TRVI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,322,500
- Market Cap $160M
- Description
- Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...